BioSpace News Archive

Functional precision oncology innovator KIYATEC announced today that it is initiating use of the 3D Predict™ Glioma test outside of its 3D-PREDICT clinical study

Luminometers find popular use in lab work in range of biomedical research, and form a key part of diagnostic research in medical sciences.

Dermatoscopy is a process through which the examination of skin lesions can be determined using an instrument, i.e., dermatoscope.

Cone calorimeter is an instrument used in the field of fire testing. Cone calorimeter test is the best method to measure the reaction of material to fire.

Bladder cancer is a urologic malignancy occurring in the tissues of the urinary bladder. It is characterized by uncontrolled, rapid growth of cells arising from the epithelial lining, which can proliferate to the muscular wall of urinary bladder.

AnPac Bio-Medical Science Co., Ltd., a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced that it had entered into an agreement with Advanced Life Therapeutics Co., Ltd., in which the Company holds a minority equity interest of 40%, to perform contract R&D on integrated circuit-based components for cancer treatment medical devices.

Medifast, Inc . (NYSE: MED), the global company behind one of the fastest-growing health and wellness communities, OPTAVIA®, will announce financial results for the second quarter ended June 30, 2021 on Wednesday, August 4, 2021 , after market close.

Inozyme Pharma, Inc. today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to INZ-701 for the treatment of ABCC6 Deficiency.

Enlivex Therapeutics Ltd. announced that its CEO, Dr. Oren Hershkovitz, will participate in, and provide an interview at, the virtual Improvate Life-Saving Technologies International Conference 2021 being held on Thursday, July 22, 2021.

In order to address a major limitation of today’s most widely used method for gauging severity of plaque psoriasis (the PASI scale), Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), in conjunction with leading psoriasis experts, has developed a revised scale that offers greater precision for measuring disease extent and therapeutic effects in patients with mild-to-moderate disease.